Therapeutic targeting of VEGF and/or TGF-β to enhance anti-PD-(L)1 therapy: The evidence from clinical trials

被引：13

作者：

Li, Linwei ^{[1
]}

Wen, Qinglian ^{[1
]}

Ding, Ruilin ^{[2
]}

机构：

[1] Southwest Med Univ, Dept Oncol, Affiliated Hosp, Luzhou, Peoples R China

[2] Southwest Med Univ, Inst Drug Clin Trial, GCP Ctr, Affiliated Hosp, Luzhou, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2022年 / 12卷

关键词：

tumor microenvironment; VEGF; TGF-beta; immunotherapy; PD-1; review; ENDOTHELIAL GROWTH-FACTOR; RENAL-CELL CARCINOMA; LENVATINIB PLUS PEMBROLIZUMAB; REGULATORY T-CELLS; PROGRAMMED DEATH 1; OPEN-LABEL; EXPANSION COHORT; SINTILIMAB PLUS; HEPATOCELLULAR-CARCINOMA; BINTRAFUSP ALPHA;

D O I：

10.3389/fonc.2022.905520

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Normalizing the tumor microenvironment (TME) is a potential strategy to improve the effectiveness of immunotherapy. Vascular endothelial growth factor (VEGF) and transforming growth factor (TGF)-beta pathways play an important role in the development and function of the TME, contributing to the immunosuppressive status of TME. To inhibit VEGF and/or TGF-beta pathways can restore TME from immunosuppressive to immune-supportive status and enhance sensitivity to immunotherapy such as programmed death protein-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) inhibitors. In this review, we described the existing preclinical and clinical evidence supporting the use of anti-VEGF and/or anti-TGF-beta therapies to enhance cancer immunotherapy. Encouragingly, adopting anti-VEGF and/or anti-TGF-beta therapies as a combination treatment with anti-PD-(L)1 therapy have been demonstrated as effective and tolerable in several solid tumors in clinical trials. Although several questions need to be solved, the clinical value of this combination strategy is worthy to be studied further.

引用

页数：13

共 106 条

[1] TGF-β1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells
Ahmadzadeh, M
Rosenberg, SA
[J]. JOURNAL OF IMMUNOLOGY, 2005, 174 (09) : 5215 - 5223
[2] Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes
Alfaro, C.
Suarez, N.
Gonzalez, A.
Solano, S.
Erro, L.
Dubrot, J.
Palazon, A.
Hervas-Stubbs, S.
Gurpide, A.
Lopez-Picazo, J. M.
Grande-Pulido, E.
Melero, I.
Perez-Gracia, J. L.
[J]. BRITISH JOURNAL OF CANCER, 2009, 100 (07) : 1111 - 1119
[3] Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
Amin, Asim
Plimack, Elizabeth R.
Ernstoff, Marc S.
Lewis, Lionel D.
Bauer, Todd M.
McDermott, David F.
Carducci, Michael
Kollmannsberger, Christian
Rini, Brian I.
Heng, Daniel Y. C.
Knox, Jennifer
Voss, Martin H.
Spratlin, Jennifer
Berghorn, Elmer
Yang, Lingfeng
Hammers, Hans J.
[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
[4] Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
Atkins, Michael B.
Plimack, Elizabeth R.
Puzanov, Igor
Fishman, Mayer N.
McDermott, David F.
Cho, Daniel C.
Vaishampayan, Ulka
George, Saby
Olencki, Thomas E.
Tarazi, Jamal C.
Rosbrook, Brad
Fernandez, Kathrine C.
Lechuga, Mariajose
Choueiri, Toni K.
[J]. LANCET ONCOLOGY, 2018, 19 (03) : 405 - 415
[5] Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)
Bang, Yung-Jue
Golan, Talia
Dahan, Laetitia
Fu, Siqing
Moreno, Victor
Park, Keunchil
Geva, Ravit
De Braud, Filippo
Wainberg, Zev A.
Reck, Martin
Goff, Laura
Laing, Naomi
Mi, Gu
Oliveira, Joana M.
Wasserstrom, Heather
Lin, Chia-Chi
[J]. EUROPEAN JOURNAL OF CANCER, 2020, 137 : 272 - 284
[6] Transforming Growth Factor-β Signaling in Immunity and Cancer
Batlle, Eduard
Massague, Joan
[J]. IMMUNITY, 2019, 50 (04) : 924 - 940
[7] Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date
Chau, Vincent
Bilusic, Marijo
[J]. CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 7321 - 7330
[8] Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort
Cho, Byoung Chul
Daste, Amaury
Ravaud, Alain
Salas, Sebastien
Isambert, Nicolas
McClay, Edward
Awada, Ahmad
Borel, Christian
Ojalvo, Laureen S.
Helwig, Christoph
Rolfe, P. Alexander
Gulley, James L.
Penel, Nicolas
[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
[9] Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Choueiri, T. K.
Powles, T.
Burotto, M.
Escudier, B.
Bourlon, M. T.
Zurawski, B.
Juarez, V. M. Oyervides
Hsieh, J. J.
Basso, U.
Shah, A. Y.
Suarez, C.
Hamzaj, A.
Goh, J. C.
Barrios, C.
Richardet, M.
Porta, C.
Kowalyszyn, R.
Feregrino, J. P.
Zolnierek, J.
Pook, D.
Kessler, E. R.
Tomita, Y.
Mizuno, R.
Bedke, J.
Zhang, J.
Maurer, M. A.
Simsek, B.
Ejzykowicz, F.
Schwab, G. M.
Apolo, A. B.
Motzer, R. J.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (09) : 829 - 841
[10] Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial
Choueiri, Toni K.
Larkin, James
Oya, Mototsugu
Thistlethwaite, Fiona
Martignoni, Marcella
Nathan, Paul
Powles, Thomas
McDermott, David
Robbins, Paul B.
Chism, David D.
Cho, Daniel
Atkins, Michael B.
Gordon, Michael S.
Gupta, Sumati
Uemura, Hirotsugu
Tomita, Yoshihiko
Compagnoni, Anna
Fowst, Camilla
di Pietro, Alessandra
Rini, Brian I.
[J]. LANCET ONCOLOGY, 2018, 19 (04) : 451 - 460

← 1 2 3 4 5 6 7 8 9 10 →